- Home
- JTAI vs CVKD Comparison
JTAI vs CVKD Comparison
Compare JTAI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- CVKD
- Stock Information
- Founded
- JTAI 2018
- CVKD 2022
- Country
- JTAI United States
- CVKD United States
- Employees
- JTAI N/A
- CVKD N/A
- Industry
- JTAI Blank Checks
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- JTAI Finance
- CVKD Health Care
- Exchange
- JTAI Nasdaq
- CVKD Nasdaq
- Market Cap
- JTAI 9.9M
- CVKD 29.5M
- IPO Year
- JTAI N/A
- CVKD 2023
- Fundamental
- Price
- JTAI $3.60
- CVKD $11.47
- Analyst Decision
- JTAI
- CVKD Strong Buy
- Analyst Count
- JTAI 0
- CVKD 1
- Target Price
- JTAI N/A
- CVKD $32.00
- AVG Volume (30 Days)
- JTAI 329.3K
- CVKD 33.0K
- Earning Date
- JTAI 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- JTAI N/A
- CVKD N/A
- EPS Growth
- JTAI N/A
- CVKD N/A
- EPS
- JTAI N/A
- CVKD N/A
- Revenue
- JTAI $13,648,668.00
- CVKD N/A
- Revenue This Year
- JTAI $13.37
- CVKD N/A
- Revenue Next Year
- JTAI $201.13
- CVKD N/A
- P/E Ratio
- JTAI N/A
- CVKD N/A
- Revenue Growth
- JTAI N/A
- CVKD N/A
- 52 Week Low
- JTAI $2.30
- CVKD $5.70
- 52 Week High
- JTAI $97.40
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- JTAI 42.57
- CVKD 40.38
- Support Level
- JTAI $3.41
- CVKD $10.02
- Resistance Level
- JTAI $3.95
- CVKD $13.71
- Average True Range (ATR)
- JTAI 0.25
- CVKD 1.08
- MACD
- JTAI 0.00
- CVKD -0.13
- Stochastic Oscillator
- JTAI 22.54
- CVKD 29.72
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.